Actively Recruiting
Phase I Study of Autologous MOv19-BBz CAR T Cells Delivered into the Chest for FRa-Positive Cancers in Patients With Metastatic or Recurrent NSCLC
Led by University of Pennsylvania · Updated on 2026-10-07
10
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, feasibility, and early effects of a new treatment using MOv19-BBz CAR T cells delivered directly into the chest area for patients with certain cancers that have a protein called FRa. The trial focuses on patients with metastatic or recurrent non-small cell lung cancer NSCLC who have not responded to standard treatments. This is a Phase I open-label study designed to explore how well this approach works and any side effects it may cause. Participants receive a single dose of MOv19-BBz CAR T cells via an infusion into the pleural space after undergoing chemotherapy to reduce immune cells. If they do not already have a catheter in the chest area, one will be placed temporarily to deliver the treatment. Patients may start treatment with standard checkpoint inhibitors at least 28 days after receiving the CAR T cells. Two dose levels are planned, with the second dose level explored only if safety concerns arise at the first dose. Throughout the study, participants will be monitored closely for adverse events and treatment-limiting toxicities up to 15 years after receiving the CAR T cells. Researchers will also assess response rates, duration of response, progression-free survival, and overall survival over this period. Organ function, disease status, and imaging will be evaluated before and after treatment. The study includes long-term follow-up to evaluate safety and treatment effects.
CONDITIONS
Brief Title
MOv19-BBz CAR T Cells in FRa+ Cancers
Research Team
A
Abramson Cancer Center Clinical Trials Service
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here